-
PurposeRetroviral expression plasmid for generating stable FCGR3A (CD16a)-expressing cell lines.
-
Depositing Lab
-
Sequence Information
Ordering
Item | Catalog # | Description | Quantity | Price (USD) | |
---|---|---|---|---|---|
Plasmid | 196189 | Standard format: Plasmid sent in bacteria as agar stab | 1 | $85 |
Backbone
-
Vector backbonepMSCV Gateway IRES GFP
-
Backbone manufacturerMark Moasser Lab
- Backbone size w/o insert (bp) 7788
- Total vector size (bp) 8553
-
Vector typeMammalian Expression, Retroviral
-
Selectable markersPuromycin
Growth in Bacteria
-
Bacterial Resistance(s)Ampicillin, 100 μg/mL
-
Growth Temperature37°C
-
Growth Strain(s)NEB Stable
-
Copy numberHigh Copy
Gene/Insert
-
Gene/Insert nameCD16a
-
Alt nameFCγRIIIa
-
Alt nameFCGR3A
-
SpeciesH. sapiens (human)
-
Insert Size (bp)765
-
Mutationchanged Phenylalanine 158 to Valine
-
GenBank IDNM_000569.8
-
Entrez GeneFCGR3A (a.k.a. CD16, CD16-II, CD16A, FCG3, FCGR3, FCGRIII, FCR-10, FCRIII, FCRIIIA, FcGRIIIA, IGFR3, IMD20)
- Promoter LTR
Cloning Information
- Cloning method Gateway Cloning
- 5′ sequencing primer pBABE 5'
- 3′ sequencing primer Puro-R (Common Sequencing Primers)
Resource Information
-
Supplemental Documents
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
- Not Available to Industry
Trademarks:
- Zeocin® is an InvivoGen trademark.
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
-
For your Materials & Methods section:
pMSCV_IRES_GFP_CD16a was a gift from Ana Ruiz-Saenz (Addgene plasmid # 196189 ; http://n2t.net/addgene:196189 ; RRID:Addgene_196189) -
For your References section:
A co-culture model system to quantify antibody-dependent cellular cytotoxicity in human breast cancer cells using an engineered natural killer cell line. Vincken R, Ruiz-Saenz A. STAR Protoc. 2023 Apr 17;4(2):102224. doi: 10.1016/j.xpro.2023.102224. 10.1016/j.xpro.2023.102224 PubMed 37071532